Irbesartán Stada

Irbesartan, the active ingredient in Irbesartán Stada, is an Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is employed to manage high blood pressure and to protect kidney function in patients with diabetes‑related kidney disease.

GNH USA supplies Irbesartán Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains, on‑time delivery, and technical support throughout the procurement process.

Irbesartan is indicated for conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease. - Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. - Diabetic nephropathy: slows progression of renal impairment in type 2 diabetes. - Proteinuria: decreases urinary protein excretion, supporting kidney protection.

Irbesartan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Elevated blood potassium

Serious or Rare Side Effects: - Angioedema - Acute kidney injury - Hepatic dysfunction

When prescribing Irbesartan, clinicians should observe several precautionary measures to ensure patient safety. - Monitor blood pressure: adjust dose if hypotension occurs. - Assess renal function: check serum creatinine and eGFR before and during therapy. - Check electrolytes: especially potassium levels to avoid hyperkalaemia. - Avoid use in pregnancy: drug is contraindicated due to fetal risk. - Use caution in elderly: start with lower dose and monitor for orthostatic symptoms. - Store at room temperature: keep in original container, protect from moisture and light.

Irbesartan can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - ACE inhibitors + Irbesartan: increased risk of hyperkalaemia and renal impairment. - Aliskiren (in diabetics): heightened risk of hypotension, renal dysfunction, and hyperkalaemia. - Potassium‑sparing diuretics: additive hyperkalaemia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Loop or thiazide diuretics: can alter volume status and potassium balance. - Lithium: increased lithium concentrations, risk of toxicity. - CYP2C9 inhibitors (e.g., fluconazole): may raise Irbesartan plasma levels.